NexgenRx Announces Significant Third Quarter Revenue and EBITDA Growth

Executive Summary

• NexgenRx reported Q3 2025 revenue of $4.62 M, up $546,714 (13.43%) year‑over‑year, and EBITDA of $887,671, an increase of $441,224 versus the prior year quarter.
• Net income rose by $440,550 YoY; cash dividends of $355,586 (common) and $33,000 (preferred) were paid in August–September 2025.
• Cash balance stood at $2.54 M as of September 30 2025, with operating expenses up 8% to $243,421 due to IT implementation, consulting, and compensation adjustments.

Key Details

• Revenue: Q3 2025 = $4,616,066; YTD = $13,513,212 (up $546,714 YoY, +13.43%).
• EBITDA: Q3 2025 = $887,671; increase of $441,224 YoY; YTD EBITDA = $2,343,703.
• Net Income: Increase of $440,550 YoY (exact figure not disclosed).
• Dividends Paid:
• Common shares: $355,586 (August–September 2025)
• Preferred shares: $33,000 (August–September 2025)
• Cash Position: $2,541,906 as of September 30 2025.
• Operating Expenses: Q3 2025 = $243,421, an 8.0% increase YoY; driven by IT implementation costs, consulting services, and compensation adjustments.
• Management Commentary: President & CEO Ron Loucks highlighted continued quarterly revenue and EBITDA growth, emphasizing free cash flow generation and a strong recurring revenue base.

Notable Quotes

“Our Q3 results reflect our continued pattern of increasing revenues and EBITDA on a quarter‑by‑quarter basis over the past several years. This continued growth cycle has positioned the Company to continue to generate free cash flow, supported by our strong recurring revenues and sales pipelines.” – Ron Loucks, President & CEO

All boilerplate, forward‑looking statements, and company background have been omitted for brevity.